Clinical trials: Gram-positive Bacterial Infections
Artificial Intelligence, Deep Learning
Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
To improve accurate diagnosis and treatment of common malignant tumors and major infectious diseases in the respiratory system, we aim to establish a large medical database that includes standardized and structured clinical…
- Conditions
- Artificial Intelligence, Deep Learning, Pathology, Molecular, Medical Informatics
- Trial name
- NCT05046366
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lung Cancer, Tuberculosis
A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy
Flexible bronchoscopy is a common procedure performed by pulmonary physicians. The use of topical anesthesia, analgesia, and sedation during flexible bronchoscopy varies among physicians, institutions and geographic locations…
- Conditions
- Lung Cancer, Tuberculosis, Sarcoidosis, Interstitial Lung Disease
- Trial name
- NCT01955824
- Testing
- 1% lignocaine, 2% lignocaine
- Where
- India
- Volunteers
- 500 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Staphylococcus Aureus Infection, Bone and Joint Infection
Recurrent S. Aureus Infections in Osteoarticular Infections
Staphylococcus aureus osteoarticular infections, in particular those associated with the presence of implant, relapse in 20% of cases.
- Trial name
- RELAPSTAPH (NCT04712123)
- Testing
- relapse due to S. aureus
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hospices Civils de Lyon
Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant
Shortening Treatment by Advancing Novel Drugs
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of moxifloxacin, PA-824, and pyrazinamide treatments with varying doses and treatment lengths from 4 to 6 months in subjects with…
- Trial name
- STAND (NCT02342886)
- Testing
- Moxifloxacin, PA-824, Pyrazinamide
- Where
- 26 sites in Georgia, Kenya and 6 more
- Volunteers
- 284 people
- Sponsor
- Global Alliance for TB Drug Development
Streptococcal Infections, Saliva Altered
Efficacy of Propolis Varnish Against Oral Biofilm
This study aims to evaluate the effectiveness of a varnish containing 15% of green propolis on Streptococcus mutans in saliva and biofilm.
- Trial name
- NCT02052973
- Testing
- Propolis varnish
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Close Contacts of Active Tuberculosis
Efficacy of Nyaditum Resae(R) Against Active TB in Georgia
The use of a supplement food like "Nyaditum resae" is a reliable opportunity to stop the progression towards active TB through the most updated knowledge of this disease:the induction of tolerance.
- Trial name
- NCT02897180
- Testing
- Nyaditum resae(R)
- Where
- Georgia
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- Fundació Institut Germans Trias i Pujol
Healthy Subjects
Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169
Open-label prospective non-comparative ascending dose randomized cohort study of single and multiple oral administration of PBTZ169 (capsules 80 mg) in healthy volunteers
- Trial name
- NCT04150224
- Testing
- PBTZ169 640 mg OD, PBTZ169 640 mg BiD, PBTZ169 960 mg SD
- Where
- Russia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Nearmedic Plus LLC
Clostridium Difficile Infection
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
The study will involve administering a single dose of investigational drug or placebo in ascending dose cohorts. This study is designed to evaluate the safety and tolerability of investigational drug as well as the efficacy of…
- Trial name
- NCT02830542
- Testing
- SER-262
- Where
- 22 sites in United States
- Volunteers
- 96 people
- Sponsor
- Seres Therapeutics, Inc.
Lung Cancer, Sarcoidosis
Comparison of Three Different Puncture Techniques in EBUS-TBNA
The purpose of this study was to compare the accuracy and sensitivity of slow-pull capillary technique, traditional suction aspiration and non negative pressure puncture in the diagnosis of mediastinal and/or hilar lymph node…
- Conditions
- Lung Cancer, Sarcoidosis, Tuberculosis
- Trial name
- NCT05628454
- Testing
- Endobronchial ultrasound-guided transbronchial needle Slow-pull capillary sampling, Endobronchial ultrasound-guided transbronchial needle aspiration, Endobronchial ultrasound-guided transbronchial needle capillary sampling
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Beijing Friendship Hospital
Staphylococcal Infections
Evaluation of Consistency of StaphVAX Manufacturing Lots
This study answers a U.S. Food and Drug Administration requirement for evaluation in people of the consistency of manufacturing of a vaccine. Subjects are randomized to one of three lots of vaccine.
- Trial name
- NCT00211991
- Testing
- S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
- Where
- United States
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Nabi Biopharmaceuticals
Smoking ( Cigarette)
Cigarette Filter Study
The overall purpose of this study is to determine the effects of using charcoal-filtered cigarettes on product perceptions, smoking behaviors, and biomarkers of exposure to tobacco-related toxicants.
- Trial name
- NCT07348679
- Testing
- Charcoal filtered cigarettes with marketing, Charcoal filtered cigarette without marketing, Non-charcoal filtered cigarettes
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- Rutgers, The State University of New Jersey
Pneumococcal Infections
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)
This study will evaluate the safety and tolerability and immunogenicity of V114 when administered to 2-month old infants. The primary hypotheses are: 1) V114 is non-inferior to Prevenar 13™ for the 13 shared serotypes between…
- Trial name
- PNEU-PED-EU-1 (NCT04031846)
- Testing
- Rotarix™, Infanrix™ hexa, V114
- Where
- 60 sites in Australia, Belgium and 7 more
- Volunteers
- 1,184 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Tetanus
The Change of the Tetanus Antibody Titer After Single Injection of Td and Simultaneous Injection of TIG With Td
The investigators want to determine whether TIG influences the formation of tetanus antibody after simultaneous tetanus vaccination according to age and the time-interval of the last tetanus vaccination.
- Trial name
- NCT01338688
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Multi-drug Resistant Tuberculosis, Extensively Drug Resistant Tuberculosis
TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB
This study evaluated the safety and tolerability of low-dose linezolid (600 mg once daily) administered for 16 weeks as part of an optimized background regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB).
- Trial name
- LiMiT (NCT00664313)
- Testing
- Linezolid
- Where
- South Africa
- Volunteers
- 36 people
- Sponsor
- Centers for Disease Control and Prevention
Pneumococcal Infection
Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)
The primary objectives of this study are to evaluate the safety and tolerability of the pneumococcal 21 valent conjugate vaccine (V116), and to evaluate the serotype-specific opsonophagocytic activity (OPA) post-vaccination with…
- Trial name
- STRIDE-8 (NCT05696080)
- Testing
- V116, PCV15, PPSV23
- Where
- 44 sites in United States, Australia and 6 more
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Tuberculosis, Refeeding Syndrome
Dietary Assessment and Prevalence of Refeeding Syndrome in High-risk TB Patients in Chhattisgarh, India
Severe tuberculosis (TB) leads to wasting and anorexia, increasing risk of the refeeding syndrome (RFS) as defined by current criteria.
- Conditions
- Tuberculosis, Refeeding Syndrome, Severe Malnutrition
- Trial name
- NCT03537170
- Where
- India
- Volunteers
- 31 people
- Sponsor
- Washington University School of Medicine
Tuberculosis, Pulmonary
Effect of Smoking Cessation on Tuberculosis Treatment Outcomes
This study was a Randomized Controlled Trial conducted at Ojha Institute of Chest Diseases, Dow University of Health Sciences, Karachi, among pulmonary tuberculosis patients
- Trial name
- NCT04848246
- Testing
- Bupropion, Behavioural Change Communication
- Where
- Pakistan
- Volunteers
- 292 people
- Sponsor
- Dow University of Health Sciences
Tuberculosis, HIV Coinfection
Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
Tuberculosis (TB) is the world's leading infectious cause of mortality and responsible for 1/3 of deaths in people living with human immunodeficiency virus (PLHIV).
- Conditions
- Tuberculosis, HIV Coinfection, Tuberculosis Infection
- Trial name
- TB_GAPS (NCT05342064)
- Testing
- patient-centered TB preventive therapy, TB preventive therapy adherence support
- Where
- 5 sites in Eswatini, Lesotho and 3 more
- Volunteers
- 6,500 people
- Sponsor
- Baylor College of Medicine
HIV, Tuberculosis
Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
The purpose of this study was to compare a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with a CFZ loading dose with the 6-month standard of care (SOC) regimen for drug-susceptible (DS) tuberculosis (TB).
- Trial name
- NCT04311502
- Testing
- Rifapentine, Rifampicin, Isoniazid
- Where
- 6 sites in Haiti, India and 3 more
- Volunteers
- 104 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridioides Difficile Infection
Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days. The purpose of this study is to provide access to SER-109 for adult subjects with recurrent Clostridioides Difficile Infection (RCDI)…
- Trial name
- NCT02437500
- Testing
- SER-109
- Sponsor
- Seres Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.